Multiple Sclerosis Drug Sales Will Reach $23.2bn in 2020

Monday 15 August 2016, Amsterdam

A new report, now available on ASDReports, forecasts that the global multiple sclerosis drugs market will generate $23.2 billion in 2020. That revenue forecast and others appear in Multiple Sclerosis Drugs Market and R&D Outlook 2016-2026: Revenue Forecasts for Leading Submarkets including Immunomodulators, Interferons, Monoclonal Antibodies and S1PR Modulators, and also Drugs Including Copaxone, Tecfidera, Avonex, Gilenya and Rebif, published by the key player in June 2016.

Arshad Ahad, a senior pharmaceutical industry analyst said: “Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS), and 2.5 million people around the world suffer from the condition. MS represents a lucrative pharmaceutical market, with a range of blockbuster therapies that are able to charge premium prices.”

“However, most of these leading therapies will face patent expiry within the next ten years, representing a crucial period for this market, and it remains to be seen whether it can maintain growth in the face of generic and biosimilar competition. Fortunately, for the market and for patients, the drugs pipeline contains many exciting therapies which could represent future blockbusters and market leaders.”